TSHR基因甲基化与PTC的关系研究
Relationship between TSHR Gene Methylation and PTC
DOI: 10.12677/WJCR.2023.134021, PDF,    科研立项经费支持
作者: 于 波, 徐 宁*, 孙玺媛, 樊伟业, 姚佳兴, 李松埔, 窦福林, 李 扬:齐齐哈尔市第一医院甲状腺外科,黑龙江 齐齐哈尔
关键词: 促甲状腺激素受体甲状腺乳头状癌基因突变甲基化Thyrotropin Receptor Papillary Thyroid Carcinoma Genemutation Methylation
摘要: 甲状腺癌是头颈部较为常见的恶性肿瘤,发病率在全球范围内呈上升趋势,病理类型以甲状腺乳头状癌(Papillary Thyroid Carcinoma, PTC)最为常见。促甲状腺激素受体(Thyroid Stimulating Hormone Receptor, TSHR)是甲状腺特异蛋白,促甲状腺激素受体基因是PTC的抑癌基因,其编码基因启动子高甲基化会引起TSHR功能异常,从而影响甲状腺功能改变,导致甲状腺疾病发生。研究表明,TSHR基因启动子高甲基化可能与PTC发病机制密切相关。现就TSHR编码基因甲基化在PTC中的研究予以综述。
Abstract: Thyroid carcinoma is a common malignant tumor in head and neck, the incidence of which is on the rise in the world. The most common pathological type is papillary thyroid carcinoma (PTC). Thyroid stimulating hormone receptor (TSHR) is a thyroid-specific protein, and the TSHR gene is a tumor suppressor gene of PTC. Hypermethylation of the promoter of its coding gene can cause abnormal function of TSHR, thus affecting the thyroid function changes, leading to thyroid disease. Studies have shown that TSHR gene promoter hypermethylation may be closely related to the pathogenesis of PTC. This article reviews the research on methylation of TSHR coding gene in PTC.
文章引用:于波, 徐宁, 孙玺媛, 樊伟业, 姚佳兴, 李松埔, 窦福林, 李扬. TSHR基因甲基化与PTC的关系研究[J]. 世界肿瘤研究, 2023, 13(4): 150-154. https://doi.org/10.12677/WJCR.2023.134021

参考文献

[1] Pan, X., Ji, P., Deng, X., Li, Z., et al. (2022) Genome-Wide Analysis of Methylation CpG Sites in Gene Promoters Identified Four Pairs of CpGs-mRNAs Associated with Lung Adenocarcinoma Prognosis. Gene, 810, Article ID: 146054.
[Google Scholar] [CrossRef] [PubMed]
[2] Hur, K., Cejas, P., Feliu, J., Goel, A., et al. (2014) Hypomethylation of Long Interspersed Nuclear Element-1 (LINE-1) Leads to Activation of Proto-Oncogenes in Human Colorectal Cancer Metastasis. Gut, 63, 635-646.
[Google Scholar] [CrossRef] [PubMed]
[3] 孙宇, 石铁锋, 于江涛, 石臣磊, 等. BRAFVI600E基因突变与甲状腺乳头状微癌预后影响因素的相关性[J]. 中国普外基础与临床杂志, 2014, 21(10): 1226-1231.
[4] D’Agostino, M., Sponziello, M., Puppin, C., et al. (2014) Different Expression of TSH Receptor and NIS Genes in Thyroid Cancer: Role of Epigenetics. Journal of Molecular Endocrinology, 52, 121-131.
[Google Scholar] [CrossRef
[5] Hattori, N., Liu, Y.Y. and Ushijima, T. (2023) DNA Methylation Analysis. In: Jenkins, B.J., Ed., Inflammation and Cancer, Methods in Molecular Biology, Vol. 2691, Springer, Berlin, 165-183.
[Google Scholar] [CrossRef] [PubMed]
[6] 李咏梅, 曹芳, 曹新, 等. 乳腺癌RASSF1A基因表达及启动子区甲基化研究[J]. 南京医科大学学报, 2006, 26(7): 496-500.
[7] 李敏, 黄在菊, 董卫红, 等. 卵巢上皮性癌组织中P16INK4A基因表达缺陷的意义及其与甲基化的关系[J]. 中华妇产科杂志, 2006, 41(6): 408-412.
[8] Xing, M., Usadel, H., Cohen, Y., et al. (2003) Methylation of the Thyroid-Stimulating Hormone Receptor Gene in Epithelial Thyroid Tumors—A Marker of Malignancy and a Cause of Gene Silencing. Cancer Research, 63, 2316-2321.
[9] Qu, M., Wan, S., Ren, B., Shen, H., et al. (2020) Association between TSHR Gene Methylation and Papillary Thyroid Cancer: A Meta-Analysis. Endocrine, 69, 508-515.
[Google Scholar] [CrossRef] [PubMed]
[10] Khan, M.S., Pandith, A.A., Masoodi, S.R., Mudassar, S., et al. (2014) Epigenetic Silencing of TSHR Gene in Thyroid Cancer Patients in Relation to Their BRAF V600E Mutation. Status Endocrine, 47, 449-455.
[Google Scholar] [CrossRef] [PubMed]
[11] Shen, C.T., Qiu, Z.L., Song, H.J., et al. (2016) miRNA-106a Directly Targeting RARB Associates with the Expression of Na(+)/I(-) Symporter in Thyroid Cancer by Regulating MAPK Signaling Pathway. Journal of Experimental & Clinical Cancer Research, 35, Article No. 101.
[Google Scholar] [CrossRef] [PubMed]
[12] 张晨, 霍倩, 李萃珍, 等. 促甲状腺激索受体基因甲基化与甲状腺乳头状关联的Meta分析[J]. 中国全科医学, 2013, 16(28): 3371-3375.
[13] Su, X., Lin, L.W., Weng, J.L., Chen, S.W., Yang, X.H., et al. (2019) TSHR rs2288496 Associated with Thyroid Hormone and Predict the Occurrence of Lymph Node Metastasis of Papillary Thyroid Cancer. Cancer Biomarkers, 26, 461-470.
[Google Scholar] [CrossRef
[14] Stephen, J.K., Chen, K.M., Merritt, J., Chitale, D., Divine, G. and Worsham, M.J. (2018) Methylation Markers Differentiate Thyroid Cancer from Benign Nodules. Journal of Endocrinological Investigation, 41, 163-170.
[Google Scholar] [CrossRef] [PubMed]
[15] Klimaitė, R., Kazokaitė, M., Kondrotienė, A., et al. (2022) The Role of TSHR, PTEN and RASSF1A Promoters’ Methylation Status for Non-Invasive Detection of Papillary Thyroid Carcinoma. Journal of Clinical Medicine, 11, Article 4917.
[Google Scholar] [CrossRef] [PubMed]
[16] Kim, W.G., Zhu, X., Kim, D.W., Zhang, L., Kebebew, E. and Cheng, S.Y. (2013) Reactivation of the Silenced Thyroid Hormone Receptor Beta Gene Expression Delays Thyroid Tumor Progression. Endocrinology, 154, 25-35.
[Google Scholar] [CrossRef] [PubMed]
[17] Fuhrer, D., Brix, K. and Biebermann, H. (2015) Understanding the Healthy Thyroid State in 2015. European Thyroid Journal, 4, 1-8.
[Google Scholar] [CrossRef] [PubMed]
[18] Jason, A., Fan, C.Y., Zou, C.L., et al. (2007) Methylation Status of Gene in Papillary Thyroid Carcinoma. Archives of Otolaryngology—Head & Neck Surgery, 133, 1006-1011.
[Google Scholar] [CrossRef] [PubMed]
[19] Brabant, G. (2008) Thyrotropin Suppressive Therapy in Thyroid Carcinoma: What Are the Targets. The Journal of Clinical Endocrinology & Metabolism, 93, 1167-1169.
[Google Scholar] [CrossRef] [PubMed]
[20] Smith, J.A., Fan, C.Y., Zou, C., et al. (2007) Methylation Status of Genes in Papillary Thyroid Carcinoma. Archives of Otolaryngology, 133, 1006-1011.
[Google Scholar] [CrossRef] [PubMed]
[21] Khatami, F., Larijani, B., Heshmat, R., Tavangar, S.M., et al. (2020) Hypermethylated RASSF1 and SLC5A8 Promoters alongside BRAFV600E Mutation as Biomarkers for Papillary Thyroid Carcinoma. Journal of Cellular Physiology, 235, 6954-6968.
[Google Scholar] [CrossRef] [PubMed]
[22] Handkiewicz-Junak, D., Czarniecka, A. and Jarzab, B. (2010) Molecular Prognostic Markers in Papillary and Follicular Thyroid Cancer: Current Status and Future Directions. Molecular and Cellular Endocrinology, 322, 8-28.
[Google Scholar] [CrossRef] [PubMed]
[23] 李君, 严丽萍, 滕晓东. 甲状腺转录因子在甲状腺良恶性病变中的表达[J]. 肿瘤学杂志, 2003, 9(1): 19-20.